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Original Article
The interplay of growth differentiation factor 15 (GDF15) 
expression and M2 macrophages during prostate 
carcinogenesis
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Dhananjay A.Chitale2, Sean R.Williamson2, Andrew G.Rundle3, Deliang Tang4 and 
Benjamin A.Rybicki1,*
1Departments of Public Health Sciences and 2Pathology, Henry Ford Hospital, Detroit, MI 48202, USA 3Departments of 
Epidemiology and 4Environmental Heath Sciences, Mailman School of Public Health, Columbia University, New York, NY 
10032, USA
*To whom correspondence should be addressed. Tel: +1-313-874-6399; Fax: 313-874-6730; Email: brybick1@hfhs.org
Abstract
M2 (tumor-supportive) macrophages may upregulate growth differentiation factor 15 (GDF15), which is highly expressed 
in prostate tumors, but the combined utility of these markers as prognostic biomarkers are unclear. We retrospectively 
studied 90 prostate cancer cases that underwent radical prostatectomy as their primary treatment and were followed 
for biochemical recurrence (BCR). These cases also had a benign prostate biopsy at least 1 year or more before their 
prostate cancer surgery. Using computer algorithms to analyze digitalized immunohistochemically stained slides, GDF15 
expression and the presence of M2 macrophages based on the relative density of CD204- and CD68-positive macrophages 
were measured in prostate: (i) benign biopsy, (ii) cancer and (iii) tumor-adjacent benign (TAB) tissue. Both M2 macrophages 
(P = 0.0004) and GDF15 (P < 0.0001) showed significant inter-region expression differences. Based on a Cox proportional 
hazards model, GDF15 expression was not associated with BCR but, in men where GDF15 expression differences between 
cancer and TAB were highest, the risk of BCR was significantly reduced (hazard ratio = 0.26; 95% confidence interval = 0.09–
0.94). In addition, cases with high levels of M2 macrophages in prostate cancer had almost a 5-fold increased risk of BCR 
(P = 0.01). Expression of GDF15 in prostate TAB was associated with M2 macrophage levels in both prostate cancer and TAB 
and appeared to moderate M2-macrophage-associated BCR risk. In summary, the relationship of GDF15 expression and 
CD204-positive M2 macrophage levels is different in a prostate tumor environment compared with an earlier benign biopsy 
and, collectively, these markers may predict aggressive disease.
Introduction
Inflammation is critical in tumor development and progression 
and can be both tumor promoting and antitumorigenic (1). In 
the prostate gland, chronic prostatitis is thought to increase the 
risk of cancer by as much as 60% (2,3). However, a more in-depth 
examination of prostatic inflammation on the histologic level 
suggests that histologic inflammation in the benign prostate 
may decrease the risk for cancer (4–6). Pre-clinical studies show 
that pathologic mechanisms associated with the activation of 
a chronic inflammatory response play an important role in the 
pathogenesis and progression of prostate cancer (7). Although 
the infiltration of inflammatory cells might be associated with 
the proliferation of prostatic glandular cells (8), eventually 
leading to cancer development, it remains unclear what types 
of inflammatory cells infiltrate and how these cells affect malig-
nant transformation.
Tumor-associated factors can polarize macrophages 
toward either the M1 (tumor-suppressive) or M2 (tumor-
supportive) direction. M1 ‘classically activated’ macrophages 
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are associated with acute inflammation and T-cell immunity 
and their function is to kill and phagocytose target cells (9). 
These macrophages express high levels of major histocom-
patibility complex class  II, the CD68 protein and CD80 and 
CD86 costimulatory molecules. M2 macrophages, also known 
as ‘alternatively activated’ macrophages, are associated with 
tumor growth and are key regulators of the link between in-
flammation and cancer. These macrophages function in re-
moving parasites, dampening the immune response and 
wound healing. M2 macrophages are identifiable by cell-
surface markers, such as hemoglobin-scavenger receptor 
(CD163), mannose receptor C type 1 (CD206) and macrophage-
scavenger receptor 1 (MSR1 or CD204) (10). In prostate, the 
mechanisms and factors that induce polarization of macro-
phages to the M2 state remains an active area of investigation 
(11).
MSR1 or CD204, is a multifunctional cell membrane scav-
enger receptor that recognizes many different types of nega-
tively charged macromolecules (12) and is reported to be 
overexpressed on M2 macrophages (13). CD204-positive macro-
phages display a large amount of plasticity and can have 
many different states along a continuum ranging between 
the extremes of the M1 and M2 phenotypes depending upon 
the signals they receive from their environment and can be 
‘repolarized’ in vitro to their opposite state (14). CD204-positive 
macrophages have been reported to correlate with tumor pro-
gression and poor patient outcome in glioma, ovarian epithe-
lial tumors, lung, pancreatic, gastric, renal, oral and esophageal 
cancers (15–20). In prostate cancer, two studies have shown that 
decreased numbers of CD204-positive cells are associated with 
a higher likelihood of cancer and cancer progression (21,22), but 
a third study found that, in men with prostate cancer, CD204 
expression is higher in cancer than in adjacent normal cells (8).
Growth differentiation factor 15 (GDF15), also known as 
macrophage inhibitory cytokine 1 (MIC-1), a divergent member 
of the transforming growth factor-β (TGF-β) superfamily of 
cytokines, appears to have a key role in regulating inflamma-
tory pathways in prostate, exhibiting both tumor-suppressing 
and tumor-promoting functions (23). GDF15 suppresses the ac-
tivity of nuclear factor-kappaB, indicating a tumor-suppressing 
quality, but has also been shown to preferentially inhibit M1 
macrophage formation, indicating a pro-tumorigenic quality 
(24). In a recent study of esophageal squamous cell carcinomas, 
M2 macrophages appeared to upregulate GDF15 expression with 
a strong positive correlation between GDF15 expression and 
CD204-positive cells (25). While this finding is intriguing, overall 
not much is known about the interplay between GDF15 and M2 
polarized macrophages in cancer development.
In the present study, we characterized the prostate inflam-
matory environment in ‘benign’ biopsy tissue, as well as overt 
malignant tumor tissue in paired prostate specimens taken be-
fore diagnosis and after the development of tumor. By measuring 
how GDF15 expression levels and location in the prostate tumor 
environment compares to benign prostate of the same indi-
vidual, as well as the dynamics of GDF15 expression in relation 
to the presence of the CD204-positive M2 macrophage pheno-
type, and how the associations of these two markers relate to 
disease outcome, a clearer understanding of the role of GDF15 
in relation to the M1–M2 transition in prostate carcinogenesis 
should start to emerge.
Materials and methods
Study sample
After obtaining appropriate approval from the Henry Ford Health System 
Institutional Review Board, we ascertained 90 prostate cancer cases with 
primary treatment of radical prostatectomy occurring between 1999 and 
2012 who also had at least one previous benign prostate biopsy 1 or more 
years before their surgery (Table 1). Surgical and benign biopsy specimens 
were on average 1504.8 days (or 4.1 years) apart with a range of 368 days 
to 16.3 years. Cases were 38% African American (AA) and 59% White with 
an average age of 63.5 and 65.1 years at the time of diagnosis, respectively. 
About 30% of tumors were considered high grade (Gleason grade group 
3 and above). To determine biochemical recurrence (BCR) for our study 
sample, we electronically retrieved all prostate-specific antigen (PSA) test 
results from the date of surgery forward. A total of 1423 PSA test results 
were retrieved, with the men in this sample having a median of 10 PSA 
tests and the number of tests ranging from 2 to 29. A BCR event was de-
fined as having two consecutive detectable rising PSA levels (>0.2 ng/ml) 4 
weeks or more after surgery. A total of 26% of cases experienced BCR with 
the median follow-up of men who did not biochemically recur 7.1 years. 
The study is a retrospective surgical sample review and a blanket consent 
for research studies are obtained at the time of surgery from the patients.
Pathological assessment of inflammation
All biopsy and prostatectomy specimens were reviewed by two inde-
pendent pathologists to exclude malignancy in the benign biopsy speci-
mens and score inflammation in the tissue. Location (acinar, peri acinar 
and stromal), extent (focal, multifocal and diffuse) and grade (mild, mod-
erate and severe) of inflammation were assessed using the Nickel criteria 
(26); when inflammatory infiltrate varied, the highest grade was recorded. 
Acute and chronic inflammations were evaluated by the distribution of 
polymorpho-nuclear leukocytes and mononuclear cells, respectively (27) 
with each specimen graded on a four-tier scale for both cell types. In each 
prostate surgical section, regions of tumor and tumor-adjacent benign 
glands were demarcated and scored separately for the primary tumor 
focus. These same regions were also used for immunohistochemistry 
(IHC) analyses described below.
Specimen processing, IHC and imaging
Surgical prostatectomy and biopsy specimens preserved as formalin-
fixed, paraffin-embedded blocks were procured from the Henry Ford 
Hospital biorepository. For biopsy specimens used for analysis, we ran-
domly selected a subset of blocks for each case from blocks with available 
tissue cores. For surgical prostatectomy specimen, one block per case with 
tumor was selected. Serial sections at 5 μm thickness were cut from both 
the biopsy and the surgical prostatectomy specimen. The middle section 
was Hematoxylin and Eosin stained and used to confirm the tumor/be-
nign status of the specimen and for histopathological assessment of in-
flammation. The remaining sections were stained for a set of immune 
cell markers using a standard IHC protocol. Slides were dried for 60 min 
in a 60°C drying oven, de-paraffinized and hydrated. Antigens were re-
trieved by boiling the slide in citrate buffer for 10 min and cooling to room 
temperature. All slides were analyzed with the Dako Autostainer Link 48 
(Dako North America, Carpinteria, CA). The following antibodies and con-
centrations were used to differentiate immune cell types: macrophages 
(anti-CD68+, IR613 from Dako) at 1:200 dilution, tumor-associated macro-
phages (TAMs; MSR1 or CD204+, HPA000272 from Sigma Life Science) at 
Abbreviations 
AA African American
BCR biochemical recurrence
CI confidence interval
GDF15 growth differentiation factor 15
HR hazard ratio
IHC immunohistochemistry
MIC-1 macrophage inhibitory cytokine 1
MSR1 macrophage-scavenger receptor 1
PSA prostate-specific antigen
TAB tumor-adjacent benign
TAM tumor-associated macrophage
TGF-β transforming growth factor-β
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1:200 dilution and cytokine growth differentiation factor 15 (MIC-1 or 
GDF15, AMAb90687 from Atlas Antibodies) at 1:1500 dilution. The ex-
pression of CD68 (pan macrophage), CD204 (M2 TAM) and GDF15 were 
analyzed as single IHC staining on adjacent sections of the surgical and 
biopsy specimens. In order to maintain similar experimental conditions 
within the pair, the matched surgical and biopsy specimens were pro-
cessed together for IHC.
Whole slide scanning of CD68, CD204 and GDF15 stained matched 
benign biopsy and prostatectomy surgical slides were performed using a 
Ventana iScan HT slide scanner (Roche Diagnostics) at ×40 magnification. 
Three glandular regions of interest that also included the surrounding 
stromal regions were delineated by the study pathologist on slides 
stained for CD68: (i) benign glands in the biopsy slides in prostatectomy 
slides, (ii) prostate cancer and 3)  tumor-adjacent benign (TAB) glands. 
Additional information about the processing and analysis of whole slide-
scanned images is provided in the Supplementary Materials (available at 
Carcinogenesis online).
Statistical analysis
For comparisons of patients with and without BCR, paired t-tests were used 
for continuous variables and chi-square tests for categorical variables. An ana-
lysis of variance was used to test for heterogeneity of mean levels of CD68- 
and CD204-positive macrophages and GDF15 expression across the three 
prostate tissue regions. P values for differences between pairs of means 
were computed with a Tukey multiple comparison adjustment. Intra- and 
inter-region comparisons of macrophage density and GDF15 expression 
were also analyzed with Pearson correlation coefficients. Macrophage 
density and GDF15 expression values were modeled both on a continuous 
and categorical scale—the latter as groups divided into tertiles or at the 
median. Analyses that considered time to BCR included log-rank tests and 
Cox proportional hazard models that analyzed the marker level differ-
ences with respect to time to BCR. Time to BCR was defined as the dur-
ation between the date of surgery and the second PSA test that defined 
the recurrence event or censored at the last post-operative PSA test for 
men that did not recur. Both unadjusted (only a covariate for the marker) 
and adjusted models were tested—the latter adjusted for advanced tumor 
stage, advanced tumor grade and PSA level at cancer diagnosis. Model 
outliers were assessed through the examination of deviance residuals 
and assumptions of linearity through the examination of Martingale re-
siduals. To determine whether the proportional hazards assumption was 
met, models were run where the singular and joint significance of each 
covariate by time interaction term was tested.
Results
Demographic and clinical characteristics of the 
study cohort
Among our study sample of 90 prostate cancer surgical cases, 
most could be classified as either White or AA (Table1). Study 
subjects had a median follow-up after surgery of over 7 years 
with 75% of subjects followed up for at least 3 years. A higher 
percentage of AA men had biochemically recurrent disease (29 
versus 24%), but racial differences were not statistically signifi-
cant. The mean age at diagnosis was not significantly different 
between men who biochemically recurred (66.2 ± 5.9 years) and 
those who did not (63.9 ± 6.5 years). PSA at the time of benign bi-
opsy was higher in men who had BCR (7.2 ± 5.4 ng/ul) compared 
to men who did not (4.4 ± 13.5 ng/ul), but the difference was not 
statistically different (P ≤ 0.35). Men who had BCR also appeared 
to have more advanced Gleason grade with biochemically re-
current cases more often having a Gleason grade group of 3 or 
higher (P ≤ 0.001).
M1/M2 macrophage density and GDF15 expression 
in different prostate regions and age effects
Macrophage density as measured by the area of CD68-
expressing cells was not significantly different between the 
three different regions of the prostate specimens examined 
(Figure 1A). However, the density of CD204 expressing macro-
phages was significantly different (P ≤ 0.0001) between benign 
biopsies and the two prostate regions examined in prostatec-
tomy specimens (cancer and TAB; Figure  1B). CD204 macro-
phage density was lowest in benign biopsy, intermediate in 
TAB and highest in cancer. GDF15 expression significantly (P 
≤ 0.0001) varied across these three regions of the prostate as 
well (Figure 1C). The highest GDF15 expression levels were in 
cancer and lowest expression in TAB with GDF15 expression 
in TAB significantly lower than expression in either cancer (P ≤ 
0.0001) or benign (P ≤ 0.007) prostate. In general, age was posi-
tively associated with CD68 levels and negatively associated 
with GDF15 expression. The age association with M2 CD204 
Table 1.  Demographic and clinical characteristics of study sample by prostate cancer biochemical recurrence (BCR) status (n = 90)
Characteristic Disease free (n = 67) BCR (n = 23) P value
Race   0.55
 White 42 (63%) 13 (57%)  
 AA 24 (36%) 10 (43%)  
 Other 1 (1%) 0  
Mean age at diagnosis 63.9 ± 6.5 66.2 ± 5.9 0.148
PSA at time of biopsy 4.4 ± 13.5 7.2 ± 5.4 0.35
Mean duration between benign biopsy and surgery dates 4.2 ± 3.3 4.5 ± 3.0 0.68
Grade group   
 1 25 (37.5%) 2 (8.7%) 0.001a
 2 28 (42%) 8 (34.8%)
 3 9 (13.5%) 10 (43.5%)  
 4 3 (4%) 0  
 5 2 (3%) 3 (13%)  
Pathological stage    
 2A 9 (13.4%) 0  0.15b
 2B 18 (26.9%) 8 (34.8%)  
 2C 25 (37.3%) 6 (26.1%)  
 3A 13 (19.4%) 6 (26.1%)  
 3B 2 (3%) 3 (13%)  
aGrade groups 1 and 2 and 3–5 combined for chi-square test.
bStages 2A–2C and 3A and 3B combined for chi-square test.
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marker was tissue dependent, with age negatively associated 
with CD204 density in prostate cancer and TAB but positively 
associated with age in prostate benign biopsy. All these as-
sociations were relatively weak, and none reached statistical 
significance (data not shown).
Correlation of M1/M2 macrophage density and 
GDF15 expression in different prostate regions
Interestingly, GDF15 expression in TAB was significantly correl-
ated with the CD204/CD68 macrophage density level in both the 
TAB (r = 0.27; P ≤ 0.009) and cancer (r = 0.26; P ≤ 0.01). Other intra- 
and inter-region correlations of these two markers were not as 
strong (Supplementary Figure 2A and Supplementary Table 1, 
available at Carcinogenesis online) with the CD204/CD68 macro-
phage density level in benign prostate biopsy having a nega-
tive, albeit non-significant, correlation with GDF15 expression 
across all three prostate tissue regions. Intra-region correlations 
of CD204/CD68 macrophage density and GDF15 expression in 
benign prostate biopsy and cancer were much lower than the 
correlation in TAB. In terms of intra-marker correlations across 
regions, CD204/CD68 macrophage density levels were strongly 
correlated between cancer and TAB (Supplementary Figure 2B 
and Supplementary Table 1, available at Carcinogenesis online), 
but levels in neither region were correlated with benign pros-
tate levels. GDF15 expression was not correlated between cancer 
and TAB regions (Supplementary Figure 2C and Supplementary 
Table 1, available at Carcinogenesis online), but there was a weak 
nominally significant correlation between GDF15 expression in 
benign prostate biopsy and TAB regions (r = 0.20; P ≤ 0.05).
Level of inflammation as measured by either grade or ex-
tent was moderately associated with the density of M2 macro-
phages expressing CD204—with macrophage density increasing 
with both inflammation grade (P ≤ 0.03) and extent (P ≤ 0.05). 
However, after adjusting for the prostate tissue region these as-
sociations were no longer observed (data not shown). On the 
other hand, adjusting for prostate tissue region resulted in a 
stronger negative association of both inflammation grade and 
extent with GDF15 expression. CD68-positive macrophages were 
strongly positively associated with the extent of inflammation 
(P ≤ 0.0002), but not inflammation grade, irrespective of whether 
the prostate tissue region was considered. In general, trends of 
marker expression with inflammation grade or extent were con-
sistent across prostate tissue regions.
M1/M2 macrophage density and GDF15 expression 
in different prostate regions and prostate cancer 
recurrence
Whether the amount and/or proportion of M1–M2 macrophages 
and/or GDF15 expression were related to prostate cancer out-
come was tested in Cox proportional hazards models of time 
to BCR after surgery (Supplementary Table 2, available at 
Carcinogenesis online). The density of CD68-positive M1 macro-
phages in different prostate regions or differences in CD68 
macrophage density between regions were not significantly 
associated with BCR. A modest increase in BCR risk was asso-
ciated with increasing CD68-positive macrophage density in 
cancer compared with the adjacent benign cells (Δ cancer/TAB), 
but this risk did not reach statistical significance [hazard ratio 
(HR) = 1.37; 95% confidence interval (CI) = 0.84, 2.25]. Adjusting 
for PSA at diagnosis, Gleason grade and pathologic stage re-
sulted in nominal risk estimate changes. Alternatively, the 
density of the M2 macrophage marker CD204 in cancer was 
associated with an increased BCR risk (HR = 1.98, P ≤ 0.002)—
with the adjusted risk estimate remaining statistically signifi-
cant. Also associated with BCR was the unadjusted risk for Δ 
cancer/benign for CD204-positive macrophages (HR = 1.26, P ≤ 
0.01). Further analysis to determine the significance of CD204-
postive macrophage density was done using a CD204/CD68 ratio 
Figure 1. Violin plot of CD68-positive macrophage density (A), CD204-positive 
macrophage density (B) and GDF15 expression (C) across prostate regions 
of benign biopsy, cancer and TAB. For (A) and (B), y-axis macrophage density 
levels represent natural log transformed percentage of positive expression 
within tissue area. GDF15 expression values on y-axis of (C) are the natural log-
transformed percentage of positive expression within tissue area multiplied by 
the pixel intensity values. Individual data points are also plotted with intensity 
of red dots representing the level of inflammation in each specimen. Mean levels 
of marker by prostate region are represented by black bars.
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to standardize the M2 macrophage measure. The ratio of CD204/
CD68 macrophages in both TAB and cancer were significantly 
associated with BCR with an approximately 35% increased risk 
in unadjusted models. Only the association in cancer remained 
significant after adjustment for clinical factors (HR = 1.35; P ≤ 
0.04). Associations with BCR were not observed for the CD204/
CD68 macrophage ratio in benign prostate biopsy or differ-
ences in CD204/CD68 macrophage ratio between regions of the 
prostate.
Potential threshold effects of either CD204/CD68 macro-
phage density and/or GDF15 expression on BCR risk were 
examined by categorizing expression levels into tertiles—
low, middle and high—and comparing risk associated with 
the middle and highest tertile to the lowest tertile (Table  2). 
For CD204/CD68 macrophage density in cancer, the highest 
tertile was associated with a statistically significant (P ≤ 0.01) 
increased risk of BCR of over 4-fold in the adjusted model. 
Although not statistically significant, there appeared to be an 
increasing trend in the risk of BCR with increasing CD204/CD68 
density in the prostate TAB region. Models of the difference in 
CD204/CD68 density between the prostate tumor and benign 
adjacent regions (Δ cancer/TAB) also had HRs around three in 
the two highest tertiles in the adjusted model, although nei-
ther HR reached statistical significance. The highest tertile of 
the Δ cancer/TAB for GDF15 expression was associated with 
the risk of BCR in the opposite direction even after adjusting for 
clinical covariates (HR = 0.29; 95% CI = 0.09, 0.94). None of the 
other models of GDF15 expression had HRs that approached 
statistical significance.
Survival analyses for time to recurrence for M1/
M2 Macrophage density and GDF15 expression in 
different prostate regions
Prostate cancer BCR with regard to levels of CD204/CD68 macro-
phage density in cancer and the difference in GDF15 expres-
sion between cancer and TAB prostate regions was further 
explored with Kaplan–Meier survival plots. Men in the lowest 
tertile of CD204/CD68 macrophage density tended to have less 
biochemically recurrent disease over time than men in the 
middle or highest tertile (Supplementary Figure 3A, available 
at Carcinogenesis online). The survival curves for the latter two 
groups did not appear to separate, and the log-rank statistic for 
this survival plot stratification was not statistically significant 
(P ≤ 0.11). In plotting out the survival curves based on the distri-
bution of the difference in GDF15 expression in cancer and TAB 
regions (Supplementary Figure 3B, available at Carcinogenesis 
online), there was a clear trend for better outcomes when the 
amount of GDF15 expression in cancer exceeded that in the TAB 
(log-rank P value ≤ 0.004). Men in the tertile with the greatest 
difference in GDF15 expression between cancer and TAB regions 
had the best outcomes compared with men in the other two 
tertiles, where the GDF15 expression in cancer was the same or 
less than in TAB having the highest BCR rate.
Table 2. Hazard ratios of prostate cancer biochemical recurrence associated with CD204/CD68 ratio density and GDF15 expression in prostate 
pre- and post-diagnosis
Unadjusted HRs Adjusted HRa
Levelb Middle tertile Highest tertile Middle tertile Highest tertile
 HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
CD204/CD68 ratio density
 Benign 0.64 (0.22, 1.84) 0.40 0.90 (0.34, 2.34) 0.82 0.82 (0.27, 2.53) 0.73 1.15 (0.43, 3.13) 0.78
 TAB 3.10 (0.97, 9.93) 0.06 3.52 (1.07, 11.59) 0.04 2.95 (0.91, 9.58) 0.07  2.24 (0.60, 8.42) 0.23
 Cancer 1.60 (0.48, 5.27) 0.44 3.97 (1.38, 11.43) 0.01 1.78 (0.52, 6.12) 0.36  4.82 (1.51, 15.43) 0.01
 Δ TAB/benign 1.30 (0.43, 3.88) 0.64 3.15 (1.10, 9.05) 0.30 1.33 (0.44, 4.00) 0.61  1.96 (0.59, 6.55) 0.27
 Δ Cancer/benign 2.46 (0.81, 7.46) 0.12 2.63 (0.88, 7.89) 0.08 2.47 (0.80, 7.58) 0.11  2.18 (0.70, 6.77) 0.18
 Δ Cancer/TAB 1.66 (0.59, 4.67) 0.34 1.41 (0.49, 4.05) 0.53 2.88 (0.88, 9.37) 0.08  3.09 (0.89, 10.69) 0.07
GDF15 expression
 Benign 0.81 (0.28, 2.33) 0.69 1.27 (0.49, 3.31) 0.62 1.48 (0.47, 4.59) 0.51  1.19 (0.43, 3.28) 0.74
 TAB 0.98 (0.34, 2.81) 0.97 1.55 (0.57, 4.17) 0.39 0.97 (0.33, 2.85) 0.96 1.32 (0.47, 3.72) 0.60
 Cancer 1.11 (0.43, 2.84) 0.84 0.52 (0.18, 1.52) 0.23 1.18 (0.45, 3.10) 0.73  0.52 (0.18, 1.55) 0.24
 Δ TAB/benign 0.44 (0.14, 1.43) 0.17 1.28 (0.52, 3.17) 0.59 0.60 (0.18, 2.01) 0.41  1.34 (0.53, 3.35) 0.44
 Δ Cancer/benign 1.35 (0.53, 3.42) 0.53 0.58 (0.19, 1.73) 0.33 1.33 (0.52, 3.45) 0.55  0.57 (0.19, 1.70) 0.31
 Δ Cancer/TAB 0.51 (0.20, 1.29) 0.15 0.28 (0.09, 0.88) 0.03 0.57 (0.22, 1.50) 0.26  0.29 (0.09, 0.94) 0.04
aAdjusted for PSA at diagnosis, Gleason grade and pathologic stage.
bReferent category is lowest tertile of expression.
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M1/M2 macrophage density and GDF15 expression 
within and between different prostate regions and 
association with prostate cancer recurrence
Further analysis was done to determine whether a different 
level of GDF15 expression and M2 macrophages in benign biopsy 
and malignant prostate and/or a different level of both markers 
within the same prostate region were associated with the risk of 
BCR. Table 3 shows models with interaction hazard ratios (IHRs) 
that address the question of whether the joint effect of each 
marker/region combination is less or greater than would be ex-
pected based on combined effects of individual risk estimates. 
One IHR showed a 17% significant (P ≤ 0.009) increased risk for 
the joint effect of CD204/CD68 ratio density in benign prostate 
biopsy and cancer, indicating a positive interaction between 
the density of CD204-positive relative to CD68-positive macro-
phages in these two prostate regions. Another IHR showed a 22% 
significant (P ≤ 0.008) decreased risk for the joint effect of GDF15 
expression and CD204/CD68 ratio density in prostate cancer, 
indicating a negative interaction between these two factors. 
Exploring these interactions more in depth in Table  4, a high 
CD204/CD68 ratio density in both benign and cancer regions 
was associated with an almost 5-fold increased risk of BCR com-
pared with men who had low levels of CD204/CD68 ratio density 
in these two regions. Furthermore, men who had a high CD204/
CD68 ratio density in benign prostate biopsy but a low level in 
cancer had a much-reduced risk of biochemical recurrence com-
pared with men whose CD204/CD68 ratio density was low in 
both prostate regions. For the prostate TAB region, the highest 
risk of prostate cancer BCR was observed for men with a high 
CD204/CD68 ratio density and low GDF15 expression. And while 
increased GDF15 expression in TAB appeared to increase the risk 
of prostate cancer BCR when CD204/CD68 ratio density was low, 
when both the CD204/CD68 ratio density and GDF15 expression 
was high in the TAB, risk of prostate BCR remained about the 
same. Figure  2A and B show the corresponding Kaplan–Meier 
survival plots for prostate cancer BCR for these two stratifica-
tions. The log-rank statistic for both the CD204/CD68 density 
levels in benign prostate biopsy and cancer (P ≤ 0.01) and the 
CD204/CD68 density and GDF15 expression levels in TAB (P ≤ 
0.05) were statistically significant.
Discussion
Prostate tumors are rich in TAMs, which can be either the cyto-
toxic M1 or protumorigenic M2 phenotype. During the course 
of prostate carcinogenesis, M2 TAMs contribute to the immuno-
suppressive microenvironment that promotes tumor growth 
and metastasis (28). Among the various cytokines that may play 
a role in prostate carcinogenesis, one of the most intriguing is 
GDF15 that appears to have pleiotropic functions in the early 
and late stages of carcinogenesis (29). Recent evidence suggests 
that macrophages that acquire M2-like characteristics may 
upregulate GDF15 expression in human cancer (25). In a study 
of men with prostate cancer treated with surgery and then fol-
lowed for BCR, we measured the co-expression of M1/M2 macro-
phages and GDF15 in paired prostate benign biopsy and tumor 
surgical specimens. Both M2 macrophage levels and GDF15 
expression were increased in prostate tumor specimens com-
pared with benign prostate biopsy; however, GDF15 expression 
showed a pattern where the lowest mean levels were observed 
in the prostate TAB and intermediate GDF15 expression levels 
were observed in benign prostate biopsy. M2 macrophages were 
Table 3. Modeling main effects and interactions of CD204/CD68 ratio density and GDF15 expression in prostate pre- and post-diagnosis on 
prostate cancer biochemical recurrence risk
Model Region(s)
First main 
effect HR
Second main 
effect HR IHR 95% CI P value
CD204/CD68 density in different prostate tissue regions Benign–TAB 1.10 1.27 1.02 (0.89–1.17) 0.73
Benign–cancer 1.28 2.51 1.17 (1.04–1.32) 0.009
TAB–cancer 0.86 1.42 0.98 (0.87–1.10) 0.72
GDF15 expression in different prostate tissue regions Benign–TAB 0.96 1.12 0.98 (0.87–1.10) 0.68
Benign–cancer 0.93 1.03 1.01 (0.91–1.12) 0.89
TAB–cancer 1.17 0.90 0.98 (0.88–1.10) 0.76
CD204/CD68 density and GDF15 expression in the same 
prostate tissue region
Benign 1.08 1.09 1.03 (0.94–1.14) 0.53
TAB 0.74 0.84 0.78 (0.64–0.94) 0.008
Cancer 0.77 1.32 0.88 (0.74–1.05) 0.15
HR, hazard ratio; IHR, interaction hazards ratio.
Table 4. Hazard ratios of prostate cancer BCR associated with multiregion combinations of CD204/CD68 ratio density and GDF15 expression in 
prostate pre- and post-diagnosis
Marker and prostate region combinationa HR 95% CI P value
Low CD204/CD68 in benign prostate and cancer 1.00 Reference  
Low CD204/CD68 in benign prostate and high CD204/CD68 in cancer 2.35 (0.55–9.92) 0.25
High CD204/CD68 in benign prostate and low CD204/CD68 in cancer 0.27 (0.03–2.54) 0.25
High CD204/CD68 in benign prostate and cancer 4.79 (1.40–16.44) 0.01
Low CD204/CD68 and low GDF15 in TAB 1.00 Reference  
Low CD204/CD68 and high GDF15 in TAB 2.39 (0.56–10.17) 0.24
High CD204/CD68 and low GDF15 in TAB 3.71 (0.89–15.38) 0.07
High CD204/CD68 and high GDF15 in TAB 2.67 (0.64–11.34) 0.18
aLow and high expression levels are defined as below and above the median level of the marker expression for the defined region
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less prevalent in benign prostate biopsy compared with pros-
tate TAB. These differences in M2 macrophages and GDF15 ex-
pression in the benign biopsy and malignant prostate were not 
uniform and, upon close examination of the expression changes 
and co-expression of these two markers, we found associations 
with risk of prostate cancer BCR after surgery.
In our study population, the risk of developing biochemically 
recurrent disease in men with prostate cancer was associated 
with the difference in expression levels of GDF15 between the 
tumor and normal-appearing regions adjacent to the prostate 
tumor. Specifically, GDF15 expression was generally found to be 
higher in prostate tumor compared with normal adjacent re-
gions but, when GDF15 expression levels in the two regions were 
reversed, the risk of prostate cancer BCR was increased. Our re-
sults are similar to those of Karan et al. (30), who showed higher 
staining for GDF15 in tumor regions compared with normal be-
nign regions in 15 prostate adenocarcinomas. These authors did 
not report any clinical or demographic information on their sam-
ples, nor was it clear whether the benign regions of the prostate 
assayed were directly adjacent to the prostate tumor. A similar 
study of 28 prostate cancer cases also found GDF15 expression to 
be higher in prostate tumor versus benign regions; however, the 
differential expression of GDF15 diminished in cases with higher 
Gleason grade (31). More recently, Jones et  al. (32) in a slightly 
smaller sample of 16 prostate cancer cases showed elevated 
MIC-1 (GDF15) expression in both prostate tumors and structur-
ally intact adjacent tissues—the latter region appearing to have 
nominally higher expression levels. Interestingly, another recent 
study of prostate intra-tumor heterogeneity found that GDF15 
expression was elevated but with a high degree of variation, sug-
gesting complex interactions between tumor cells and the tumor 
microenvironment via GDF15 (33).
Our results suggest that GDF15 expression as a biomarker 
for prostate cancer BCR should be analyzed relative to its ex-
pression in the prostate tumor and adjacent benign regions. In 
a large prospective cohort study of men with a pathologically 
verified diagnosis of prostate cancer, the authors found that ele-
vated levels of GDF15 in serum taken at the time of diagnosis 
was predictive of prostate cancer mortality (34). Nakamura et al. 
(35) extensively analyzed the tumors of 66 men who underwent 
prostatectomy and found upregulation of MIC-1 in prostate 
cancer and in advanced and more aggressive prostatic tumors 
based on Gleason grade, suggesting that the MIC-1 protein 
should be evaluated as a potential diagnostic and prognostic 
biomarker. In the largest study to date of GDF15 expression in 
over 600 prostate tumors, we found that GDF15 expression was 
elevated in prostate cancer compared to benign, but only in AA 
men did prostate tumors show altered expression of GDF15 ac-
cording to pathologic stage or grade (36). To our knowledge, the 
expression of GDF15 in prostate as a marker for prostate cancer 
outcomes has not been investigated previously, and our finding 
that the difference in GDF15 between the tumor and adjacent 
benign region is the strongest predictor of BCR is consistent 
with the suspected diverse role of GDF in prostate carcinogen-
esis and suggests that GDF15 can either suppress or promote 
cancer depending on whether it is expressed in tumor or the 
surrounding adjacent benign regions.
We have also shown that macrophages expressing the M2 
marker CD204 are at an increased concentration in the tumor 
and adjacent benign regions of the prostate compared with an 
earlier benign prostate biopsy. Moreover, when this M2 marker is 
elevated in either tumor or adjacent benign regions of the pros-
tate, the risk of prostate cancer BCR is also increased. Elevated 
levels of M2 macrophages has been shown to be a marker of 
worse prognosis for several cancers, including breast (37,38), 
bladder (39), colon (40), lung (41,42) and pancreas (43). In pros-
tate cancer, Fujii et al. (8) found that the ratio of the M2 marker 
CD204 to the pan-macrophage marker CD68 increased steadily 
from benign prostate to high-grade prostatic intra-epitheleal 
neoplasia to prostate cancer, which is consistent with the dif-
ferences we found between benign prostate biopsy and prostate 
tumors. In terms of prognosis, a recent study showed that men 
with high numbers of M2 macrophages in the prostate tumor 
environment, as measured by the M2 maker CD163, had in-
creased odds of dying of prostate cancer (44). Another study of 
93 prostate cancer surgical patients using CD163 found that the 
M2 phenotype was significantly associated with extracapsular 
tumor extension but not biochemcial recurrence (45). In our 
study, men in the highest tertile of CD204 positive macrophage 
density in either prostate tumor or the adjacent normal tissue 
had a 4-fold increased risk of prostate cancer BCR.
M2 phenotype macrophages appear to increase in a stepwise 
fashion from normal (i.e., no inflammation) prostate tissue, to 
primary untreated carcinomas, to hormone-naïve regional lymph 
Figure 2. Kaplan–Meier survival plots of prostate cancer BCR with respect to levels of CD204/CD68 Macrophage density in prostate cancer and benign biopsy (A) and 
the combined CD204/CD68 macrophage density and GDF15 expression in prostate TAB (B).
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node metastases, to metastatic castrate-resistant prostate cancer 
(46). Interestingly, Nonomura et al. (21) found that the count of M2 
positive macrophages in benign biopsy was predictive of a later 
positive prostate cancer biopsy. In our study, M2 macrophage 
density in benign prostate biopsy was not predictive of prostate 
cancer BCR, but M2 macrophage density in benign prostate was 
predictive of prostate cancer outcome when taking into account 
the M2 macrophage density in prostate tumor. Specifically, a low 
M2 macrophage density in benign prostate biopsy and a high M2 
macrophage density in prostate tumor were associated with an 
increased risk of prostate cancer BCR, but a high M2 macrophage 
density observed in benign prostate biopsy but not in prostate 
tumor was associated with a lower risk of prostate BCR. This 
demonstrates the dynamic state of the M2 phenotype in prostate 
and raises the possibility of devising treatments to manipulate 
this phenotype for better prostate cancer outcomes (47).
Our study provided the opportunity to evaluate the po-
tential effect of GDF15 expression in relation to the density of 
M2 macrophages in prostate—a marker indicative of a more 
tumorigenic state. Examination of the expression profile of the 
M2 phase macrophages and GDF15 in prostate tumor regions 
suggested that GDF15 may moderate the effects of M2 macro-
phages on prostate cancer progression. We showed that men 
with the highest level of M2 macrophages in prostate tumor 
had almost a 5-fold increased risk of prostate cancer BCR. An in-
creased risk of BCR was also observed for M2 macrophages in 
benign glands adjacent to tumor but, when GDF15 expression 
levels in these benign glands were also high, the increased risk of 
BCR-associated elevated M2 macrophages appeared to be damp-
ened. This suggests an antagonistic effect of GDF15 on M2-driven 
carcinogenisis. In fact, GDF15 expression in benign glands ad-
jacent to tumor was more strongly correlated with M2 macro-
phage levels in tumor and benign glands adjacent to tumor than 
it was with GDF15 expression in tumor. A possible explanation 
for this observation is that GDF15 is produced in response to M2 
macrophages in benign prostate, but this response is diminished 
upon malignant transformation. In those instances when GDF15 
is still abundant in tumor relative to the surrounding benign 
glands, the cancer progression appears to be slowed. A study in 
esophageal cancer suggests that M2 phenotype macrophages 
may upregulate GDF15 and that TAMs may express GDF15 (25). In 
prostate cancer, another cytokine, pigment epithelium-derived 
factor, has been shown to act directly on monocytes/macro-
phages by inducing their migration and differentiation into 
M1-type cells (48). Whether GDF15 is expressed by M2 macro-
phages and/or suppresses these tumorigenic macrophages 
by some type of feedback loop will require additional basic re-
search. However, our results suggest that GDF15 may have some 
therapeutic potential in M2-driven prostate cancers.
Our study has several unique features that allowed us to in-
vestigate the dynamics of inflammatory environment in pros-
tate carcinogenesis and also make inferences about how the 
change in prostate histology may affect prostate cancer out-
comes. In analyzing markers of inflammation in paired prostate 
benign biopsies and subsequent prostate tumor and adjacent 
benign tissue, we had observation windows of both the pre- and 
post-malignant prostate and could investigate how changing 
levels of M2 macrophage and GDF15 might influence subse-
quent cancer progression. Because our study was observational, 
both the timing of the benign prostate biopsy and the follow-up 
after prostate cancer surgery were driven by medical cause and, 
therefore, not systematic. However, most of our study popula-
tion had robust follow-up and benign biopsies had to occur at 
least 1 year before the surgery date, which should have excluded 
biopsies that were more likely to be tissue samples from normal 
tissue adjacent to a tumor missed on biopsy. Biopsies of all po-
tential study cases were reviewed by one or more pathologists 
and those with any evidence of malignancy were excluded from 
the study. Our study is also limited by the amount of tissue spe-
cimen available for immunohistochemical analysis, especially 
with regard to biopsies, which precluded having a complete pic-
ture of the inflammatory environment in prostate. However, all 
tissue specimens were systematically selected and, while the 
number of analyzable biopsy cores was variable, we found no 
association of marker expression with the number of cores ana-
lyzed. Our study sample size was modest and, therefore, gen-
erally precluded making precise risk estimates. Most previous 
studies of GDF15 expression in prostate have had even smaller 
sample sizes (30,32,35), and our study is the first to examine the 
association of prostate GDF15 expression in relation to prostate 
cancer BCR, as well as the joint effects of GDF15 expression and 
M2 macrophage density. Using a computer-generated algorithm 
for measuring marker expression provided an unbiased quan-
titative expression score. In addition, our racially heterogenous 
sample increased the generalizability of our findings.
In summary, we have shown that, in men with prostate 
cancer and with a previous benign biopsy, an emerging M2 
macrophage environment increases the risk for biochemically 
recurrent disease. Furthermore, GDF15 may have modifying 
effects on the carcinogenic potential of the M2 macrophage 
phenotype, particularly when it is expressed to a greater degree 
in normal-appearing glands adjacent to tumor compared with 
the tumor region. As M2 macrophage markers are developed 
into clinical tests for risk prediction of aggressive cancers, in-
corporation of GDF15 expression can potentially help such risk 
prediction tools. GDF15 should also be further investigated for 
its therapeutic potential in M2-driven prostate cancer. Further 
evaluation of these dynamics in the prostate immune cellular 
profile in the pre- and post-malignant prostate may offer insight 
into inflammatory-mediated prostate carcinogenesis.
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